Perceptive Advisors CELC Position
Active12-Fund ConvergencePerceptive Advisors increased their position in Celcuity Inc. (CELC) in Q4 2025, holding $315.2M worth of shares across 3,160,200 shares.
The position was first reported in Q4 2023 and has been tracked across 9 quarterly 13F filings.
CELC is a convergence signal: 12 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Gedatolisib in 75 days (Jun 30, 2026), making the timing of Perceptive's position particularly relevant.
Short interest stands at 20.9% of float with 17.3 days to cover, indicating significant bearish positioning against Perceptive's long thesis.
About Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Full company profile →Short Interest
20.9%
17.3 days to cover
Perceptive Advisors CELC Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Increased | 3,160,200 | +203,881 | $315.2M |
| Q3 2025 | Increased | 2,956,319 | +1,323,111 | $146.0M |
| Q2 2025 | Decreased | 1,633,208 | -729,071 | $21.8M |
| Q1 2025 | Held | 2,362,279 | — | $23.9M |
| Q4 2024 | Held | 2,362,279 | — | $30.9M |
| Q3 2024 | Held | 2,362,279 | — | $35.2M |
| Q2 2024 | Held | 2,362,279 | — | $38.7M |
| Q1 2024 | Increased | 2,362,279 | +880,979 | $51.0M |
| Q4 2023 | New | 1,481,300 | +1,481,300 | $21.6M |
Frequently Asked Questions
Does Perceptive Advisors own CELC?
Yes. As of Q4 2025, Perceptive Advisors holds 3,160,200 shares of Celcuity Inc. (CELC) valued at $315.2M. This data comes from their SEC 13F filing.
How many hedge funds own CELC?
12 specialist biotech hedge funds currently hold CELC, including Baker Bros. Advisors, Avoro Capital Advisors, Deerfield Management and 8 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy CELC?
Perceptive Advisors's position in CELC was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's CELC position increasing or decreasing?
Perceptive Advisors increased their CELC position in the most recent quarter, adding 203,881 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CELCCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →